Latest from
BioRich International
NAPPA Founding Team Kick-off Meeting in Boston
BioRich International President John Xu joined the founding team of the North America Pharmaceutical Partnership Alliance (NAPPA) for its inaugural kick-off meeting in Boston, attended by key industry leaders across the US-China biopharma corridor.
BioRich at BIO International Convention 2026
The BioRich team will be attending BIO International Convention in San Diego, June 16–19. Contact us to schedule a partnering meeting or connect at the event.
John Xu to Present at China Healthcare Investment Conference
BioRich founder John Xu will present on US-China deal structures in a post-regulatory-reform environment at the China Healthcare Investment Conference in Shanghai, May 14–15.
Five Critical Mistakes in US-China Biotech Licensing Deals
Drawing on eight years of facilitating cross-border transactions, we outline the five most common and costly mistakes that Chinese biotechs and US pharmaceutical companies make when approaching licensing deals — and how to avoid them.
The Significance of Rare Disease in Pharma and the China Opportunity
The rare disease sector has emerged as one of the most promising areas for US-China biopharma collaboration. We examine the drivers, regulatory tailwinds, and deal considerations that make rare disease an increasingly attractive cross-border opportunity.
Navigating Pharma Partnerships Between the US and China in 2026
A practical guide to the key considerations, relationship-building strategies, and regulatory frameworks that define successful US-China pharmaceutical partnerships in the current environment.